Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus SEFFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus SEFFIN.
CEFOTAN IN PLASTIC CONTAINER vs SEFFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and cross-linking of peptidoglycan. It has broad-spectrum activity against gram-negative and gram-positive bacteria, including anaerobes, and is resistant to beta-lactamases.
SEFFIN is a brand name for cefazolin, a first-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms.
1 to 2 g intravenously or intramuscularly every 12 hours for 5 to 10 days. Maximum dose 6 g daily.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
None Documented
None Documented
2.8-3.2 hours in normal renal function; prolonged to 12-30 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 0.5-1 hour in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (76-85% unchanged in urine via glomerular filtration and tubular secretion); biliary excretion accounts for <10%, with small amounts in feces.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary excretion (<5%) and fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic